Thromboembolic Pulmonary Hypertension — Patent Landscape
2
Approved drugs
184
Active US patents
59/100
Avg vulnerability
$2.0B
Annual revenue covered
Originators in Thromboembolic Pulmonary Hypertension
Cliff calendar — next 15 years
9
26
15
27
50
28
17
29
41
30
9
31
5
35
16
36
16
37
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Uptravi
SELEXIPAG
|
AstraZeneca | 104 | 63 | — | 2026-10-31 |
|
Remodulin
TREPROSTINIL
|
United Therap | 80 | 54 | $2.0B | 2027-05-14 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 11357782 | Remodulin | method of use | 93 | 2027-05-14 |
| 11357782 | Remodulin | method of use | 93 | 2027-05-14 |
| 11357782 | Remodulin | method of use | 93 | 2027-05-14 |
| 11357782 | Remodulin | method of use | 93 | 2027-05-14 |
| 11357782 | Remodulin | method of use | 93 | 2027-05-14 |
| 8653137 | Remodulin | method of use | 83 | 2028-09-05 |
| 8658694 | Remodulin | method of use | 83 | 2028-09-05 |
| 8658694 | Remodulin | method of use | 83 | 2028-09-05 |
| 8653137 | Remodulin | method of use | 83 | 2028-09-05 |
| 8658694 | Remodulin | method of use | 83 | 2028-09-05 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 8791122 | Uptravi | composition of matter | 10 | 2030-08-01 |
| 8791122 | Uptravi | composition of matter | 10 | 2030-08-01 |
| 8791122 | Uptravi | composition of matter | 10 | 2030-08-01 |
| 8791122 | Uptravi | composition of matter | 10 | 2030-08-01 |
| 8791122 | Uptravi | composition of matter | 10 | 2030-08-01 |
| 8791122 | Uptravi | composition of matter | 10 | 2030-08-01 |
| 8791122 | Uptravi | composition of matter | 10 | 2030-08-01 |
| 8791122 | Uptravi | composition of matter | 10 | 2030-08-01 |
| 8791122 | Uptravi | composition of matter | 10 | 2030-08-01 |
| 9593066 | Remodulin | composition of matter | 17 | 2028-12-15 |
Related
- Thromboembolic Pulmonary Hypertension — full disease profile
- AI Patent Landscape Report — type "thromboembolic pulmonary hypertension" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner